Syros Pharmaceuticals Inc (NASDAQ:SYRS) Director Richard A. Young sold 25,000 shares of Syros Pharmaceuticals stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $10.00, for a total transaction of $250,000.00. The sale was disclosed in a filing with the SEC, which is available through this link.
SYRS traded up $0.09 during midday trading on Monday, hitting $11.17. The company had a trading volume of 199,458 shares, compared to its average volume of 179,801. The company has a debt-to-equity ratio of 0.15, a quick ratio of 8.11 and a current ratio of 8.11. The company has a market capitalization of $418.02 million, a PE ratio of -5.85 and a beta of 1.94. Syros Pharmaceuticals Inc has a twelve month low of $5.17 and a twelve month high of $13.16. The firm’s 50-day simple moving average is $8.37 and its 200-day simple moving average is $7.41.
Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings data on Thursday, August 1st. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.06). The company had revenue of $0.46 million during the quarter, compared to analyst estimates of $0.42 million. Syros Pharmaceuticals had a negative net margin of 3,137.55% and a negative return on equity of 79.79%. As a group, sell-side analysts anticipate that Syros Pharmaceuticals Inc will post -1.94 EPS for the current fiscal year.
Several equities analysts recently issued reports on the stock. HC Wainwright reissued a “neutral” rating on shares of Syros Pharmaceuticals in a report on Thursday, May 2nd. Roth Capital assumed coverage on shares of Syros Pharmaceuticals in a report on Friday, July 12th. They set a “buy” rating and a $17.00 price target for the company. Wedbush reissued an “outperform” rating and set a $13.00 price target on shares of Syros Pharmaceuticals in a report on Thursday, April 25th. ValuEngine raised shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, June 26th. Finally, BidaskClub raised shares of Syros Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, July 12th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $16.03.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients.
Featured Article: Why is the price target of stocks important?
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.